David Kerstein

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 976 citations · Full text

Medicine, Oncology, Pharmacology +13

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2017 · 583 citations · Full text

Medicine, Oncology, Pharmacology +15

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer et al. · The Lancet Oncology · 2016 · 350 citations

Medicine, Oncology, Pharmacology +14

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

D. Ross Camidge, Dong‐Wan Kim, Marcello Tiseo et al. · Journal of Clinical Oncology · 2018 · 145 citations

Medicine, Oncology, Pharmacology +16

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Rudolf M. Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez et al. · Journal of Thoracic Oncology · 2019 · 144 citations · Full text

Medicine, Oncology, Pharmacology +14